Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 15-May-24 5:28 PM View:  | Yerxa Benjamin R Director | Clearside Biomedical, Inc. (CLSD) | 15-May-24 | Private Purchase | 7,813 | $1.31 | $10,235.00 | 77% 10.14K to 17.96K | |
| 19-Apr-24 9:45 AM View: | Gibney Anthony S Director | Clearside Biomedical, Inc. (CLSD) | 18-Apr-24 | Purchase | 93,290 | $1.30 | $121,277.00 | 1390% 6.71K to 100.0K | |
| 19-Apr-24 9:45 AM View: | Gibney Anthony S Director | Clearside Biomedical, Inc. (CLSD) | 17-Apr-24 | Private Purchase | 6,710 | $1.25 | $8,387.50 | 100% 0 to 6.71K | |
| 20-Mar-24 4:30 PM View: | Chong Ngai Hang Victor CHIEF MEDICAL OFFICER | Clearside Biomedical, Inc. (CLSD) | 20-Mar-24 | Private Purchase | 30,000 | $1.60 | $48,000.00 | 100% 0 to 30.0K | |
| 09-Feb-24 1:00 PM View: | Whitmore Bradford T 10% Owner | Clearside Biomedical, Inc. (CLSD) | 07-Feb-24 | Private Purchase | 444,444 | $1.35 | $599,999.00 | 7% 6.4M to 6.85M | |
| 19-Jan-24 6:26 PM View: | Lasezkay George M CEO Director | Clearside Biomedical, Inc. (CLSD) | 19-Jan-24 | Sale | 18,000 | $1.27 | $22,860.00 | (4%) 484.58K to 466.58K | |
| 19-Jan-24 6:25 PM View: | Deignan Charles A. Chief Financial Officer | Clearside Biomedical, Inc. (CLSD) | 19-Jan-24 | Sale | 12,900 | $1.28 | $16,512.00 | (3%) 397.56K to 384.66K | |
| 01-Nov-23 4:24 PM View: | Whitmore Bradford T 10% Owner | Clearside Biomedical, Inc. (CLSD) | 01-Nov-23 | Purchase | 64,366 | $0.74 | $47,901.20 | 1% 6.34M to 6.4M | |
| 01-Nov-23 4:24 PM View: | Whitmore Bradford T 10% Owner | Clearside Biomedical, Inc. (CLSD) | 31-Oct-23 | Purchase | 70,812 | $0.73 | $51,537.00 | 1% 6.27M to 6.34M | |
| 01-Nov-23 4:24 PM View: | Whitmore Bradford T 10% Owner | Clearside Biomedical, Inc. (CLSD) | 30-Oct-23 | Private Purchase | 600 | $0.69 | $411.00 | < 1% 6.26M to 6.27M | |
| 04-Oct-23 5:06 PM View: | Hutson Nancy J Director | Clearside Biomedical, Inc. (CLSD) | 03-Oct-23 | Private Purchase | 10,000 | $0.86 | $8,600.00 | 12% 83.0K to 93.0K | |
| 25-Sep-23 4:34 PM View: | Thorp Clay Director | Clearside Biomedical, Inc. (CLSD) | 25-Sep-23 | Private Purchase | 10,000 | $0.86 | $8,600.00 | < 1% 3.58M to 3.59M | |
| 22-Sep-23 4:35 PM View: | Humphries William D. Director | Clearside Biomedical, Inc. (CLSD) | 22-Sep-23 | Option Exercise | 22,727 | $0.40 | $9,090.80 | 80% 28.31K to 51.04K | |
| 13-Sep-23 6:55 PM View: | Deignan Charles A. Chief Financial Officer | Clearside Biomedical, Inc. (CLSD) | 13-Sep-23 | Option Exercise | 34,090 | $0.40 | $13,636.00 | 9% 363.47K to 397.56K | |
| 20-Jan-23 4:32 PM View: | Ciulla Thomas Chief Medical Officer | Clearside Biomedical, Inc. (CLSD) | 20-Jan-23 | Sale (Planned) | 13,700 | $1.47 | $20,139.00 | (4%) 305.59K to 291.89K | |
| 20-Jan-23 4:31 PM View: | Lasezkay George M CEO Director | Clearside Biomedical, Inc. (CLSD) | 19-Jan-23 | Sale (Planned) | 20,030 | $1.46 | $29,243.80 | (4%) 504.61K to 484.58K | |
| 20-Jan-23 4:29 PM View: | Deignan Charles A. Chief Financial Officer | Clearside Biomedical, Inc. (CLSD) | 19-Jan-23 | Sale (Planned) | 14,030 | $1.50 | $21,045.00 | (4%) 377.5K to 363.47K | |
| 11-Jan-23 4:39 PM View: | Ciulla Thomas Chief Medical Officer | Clearside Biomedical, Inc. (CLSD) | 10-Jan-23 | Sale (Planned) | 2,170 | $1.62 | $3,515.40 | (< 1%) 307.76K to 305.59K | |
| 06-Jan-23 4:27 PM View: | Ciulla Thomas Chief Medical Officer | Clearside Biomedical, Inc. (CLSD) | 31-Dec-22 | Grant | 5,000 | $0.95 | $4,750.00 | 2% 302.76K to 307.76K | |
| 21-Dec-22 4:26 PM View: | Thorp Clay Director | Clearside Biomedical, Inc. (CLSD) | 21-Dec-22 | Private Purchase | 14,000 | $1.02 | $14,266.00 | < 1% 3.56M to 3.58M | |
| 20-Dec-22 4:38 PM View: | Deignan Charles A. Chief Financial Officer | Clearside Biomedical, Inc. (CLSD) | 20-Dec-22 | Option Exercise | 23,636 | $0.40 | $9,454.40 | 7% 353.87K to 377.5K | |
| 19-Dec-22 7:41 PM View: | Thorp Clay Director | Clearside Biomedical, Inc. (CLSD) | 15-Dec-22 | Acquisition (other) | 8,522 | -- | -- | < 1% 4.96M to 4.97M | |
| 19-Dec-22 7:41 PM View: | Thorp Clay Director | Clearside Biomedical, Inc. (CLSD) | 15-Dec-22 | Disposition (other) | 1,406,510 | -- | -- | (28%) 4.97M to 3.56M | |
| 21-Nov-22 8:12 AM View: | Hutson Nancy J Director | Clearside Biomedical, Inc. (CLSD) | 17-Nov-22 | Private Purchase | 30,000 | $1.33 | $39,900.00 | 57% 53.0K to 83.0K | |
| 06-Jan-23 4:27 PM View: | Ciulla Thomas Chief Medical Officer | Clearside Biomedical, Inc. (CLSD) | 30-Jun-22 | Grant | 5,000 | $1.25 | $6,250.00 | 2% 297.76K to 302.76K | |
| 20-Jan-22 7:06 PM View: | Ciulla Thomas Chief Medical Officer | Clearside Biomedical, Inc. (CLSD) | 19-Jan-22 | Sale (Planned) | 9,050 | $2.13 | $19,276.50 | (3%) 304.31K to 295.26K | |
| 20-Jan-22 7:04 PM View: | Lasezkay George M CEO Director | Clearside Biomedical, Inc. (CLSD) | 19-Jan-22 | Sale (Planned) | 10,800 | $2.12 | $22,896.00 | (2%) 515.41K to 504.61K | |
| 20-Jan-22 7:07 PM View: | Deignan Charles A. Chief Financial Officer | Clearside Biomedical, Inc. (CLSD) | 19-Jan-22 | Sale (Planned) | 8,833 | $2.09 | $18,461.00 | (2%) 360.2K to 351.37K | |
| 20-Jan-22 7:07 PM View: | Deignan Charles A. Chief Financial Officer | Clearside Biomedical, Inc. (CLSD) | 18-Jan-22 | Grant | 43,750 | -- | -- | 14% 316.45K to 360.2K | |
| 20-Jan-22 7:06 PM View: | Ciulla Thomas Chief Medical Officer | Clearside Biomedical, Inc. (CLSD) | 18-Jan-22 | Grant | 43,750 | -- | -- | 17% 255.56K to 299.31K | |
| 20-Jan-22 7:04 PM View: | Lasezkay George M CEO Director | Clearside Biomedical, Inc. (CLSD) | 18-Jan-22 | Grant | 97,500 | -- | -- | 23% 417.91K to 515.41K | |
| 13-Jan-22 4:40 PM View: | Lasezkay George M CEO Director | Clearside Biomedical, Inc. (CLSD) | 11-Jan-22 | Market Sale (Planned) | 5,100 | $2.46 | $12,546.00 | (1%) 423.01K to 417.91K | < 1% |
| 11-Jan-22 4:45 PM View: | Humphries William D. Director | Clearside Biomedical, Inc. (CLSD) | 10-Jan-22 | Option Exercise | 22,727 | $0.15 | $3,409.05 | 407% 5.59K to 28.31K | |
| 02-Nov-21 4:40 PM View: | Hutson Nancy J Director | Clearside Biomedical, Inc. (CLSD) | 29-Oct-21 | Option Exercise | 40,000 | $2.03 | $81,350.00 | 308% 13.0K to 53.0K | |
| 23-Sep-21 10:00 PM View: | Deignan Charles A. Chief Financial Officer | Clearside Biomedical, Inc. (CLSD) | 21-Sep-21 | Market Sale (Planned) | 2,800 | $6.41 | $17,948.00 | (< 1%) 319.25K to 316.45K | (7%) |
| 23-Sep-21 10:00 PM View: | Lasezkay George M CEO Director | Clearside Biomedical, Inc. (CLSD) | 21-Sep-21 | Market Sale (Planned) | 3,525 | $6.46 | $22,771.50 | (< 1%) 426.53K to 423.01K | (6%) |
| 23-Sep-21 10:00 PM View: | Ciulla Thomas Chief Medical Officer | Clearside Biomedical, Inc. (CLSD) | 21-Sep-21 | Market Sale (Planned) | 2,560 | $6.40 | $16,384.00 | (< 1%) 258.12K to 255.56K | (7%) |
| 17-Aug-21 10:00 PM View: | Hutson Nancy J Director | Clearside Biomedical, Inc. (CLSD) | 16-Aug-21 | Market Purchase | 3,000 | $5.68 | $17,040.00 | 30% 10.0K to 13.0K | (7%) |
| 23-Jun-21 5:43 PM View: | Lasezkay George M CEO Director | Clearside Biomedical, Inc. (CLSD) | 21-Jun-21 | Market Sale (Planned) | 3,707 | $4.38 | $16,236.70 | (< 1%) 430.24K to 426.53K | (4%) |
| 23-Jun-21 5:42 PM View: | Deignan Charles A. Chief Financial Officer | Clearside Biomedical, Inc. (CLSD) | 21-Jun-21 | Market Sale (Planned) | 2,938 | $4.37 | $12,839.10 | (< 1%) 322.19K to 319.25K | (4%) |
| 23-Mar-21 5:16 PM View: | Lasezkay George M CEO Director | Clearside Biomedical, Inc. (CLSD) | 19-Mar-21 | Market Sale (Planned) | 3,370 | $2.82 | $9,503.40 | (< 1%) 433.61K to 430.24K | 9% |
| 15-Mar-21 4:50 PM View: | Hutson Nancy J Director | Clearside Biomedical, Inc. (CLSD) | 12-Mar-21 | Market Purchase | 5,000 | $3.11 | $15,525.00 | 100% 5.0K to 10.0K | (17%) |
| 03-Mar-21 7:33 PM View: | Lasezkay George M CEO Director | Clearside Biomedical, Inc. (CLSD) | 02-Mar-21 | Market Sale (Planned) | 6,000 | $3.37 | $20,220.00 | (1%) 439.61K to 433.61K | 24% |
| 12-Feb-21 5:22 PM View: | Thorp Clay Director | Clearside Biomedical, Inc. (CLSD) | 10-Feb-21 | Market Sale (Planned) | 32,873 | $4.43 | $145,627.00 | (< 1%) 3.47M to 3.44M | 42% |
| 20-Jan-21 6:17 PM View: | Ciulla Thomas Chief Medical Officer | Clearside Biomedical, Inc. (CLSD) | 18-Jan-21 | Grant | 103,125 | -- | -- | 69% 150.0K to 253.12K | |
| 20-Jan-21 6:19 PM View: | Lasezkay George M CEO Director | Clearside Biomedical, Inc. (CLSD) | 18-Jan-21 | Grant | 140,250 | -- | -- | 47% 299.36K to 439.61K | |
| 20-Jan-21 6:18 PM View: | Deignan Charles A. Chief Financial Officer | Clearside Biomedical, Inc. (CLSD) | 18-Jan-21 | Grant | 96,360 | -- | -- | 43% 225.83K to 322.19K | |
| 07-Jan-21 9:49 AM View: | Whitmore Bradford T 10% Owner | Clearside Biomedical, Inc. (CLSD) | 06-Jan-21 | Private Purchase | 350,750 | $2.85 | $999,988.00 | 6% 6.01M to 6.37M | |
| 28-Dec-20 10:30 AM View: | Whitmore Bradford T 10% Owner | Clearside Biomedical, Inc. (CLSD) | 24-Dec-20 | Market Purchase | 51,195 | $1.95 | $99,896.80 | < 1% 5.96M to 6.01M | 32% |
| 23-Dec-20 4:28 PM View: | Lasezkay George M CEO Director | Clearside Biomedical, Inc. (CLSD) | 21-Dec-20 | Market Sale (Planned) | 3,330 | $2.07 | $6,893.10 | (1%) 302.69K to 299.36K | (24%) |
